

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 05D1077766	(X3) Date Survey Completed 01/22/2025
Name of Provider or Supplier Beverly Hills Cancer Center	Street Address, City, State 8900 Wilshire Blvd, Beverly Hills, CA	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2087	<p>ROUTINE CHEMISTRY CFR(s): 493.841(a)</p> <p>(a) Failure to attain a score of at least 80 percent of acceptable responses for each analyte in each testing event is unsatisfactory analyte performance for the testing event.</p> <p>This STANDARD is not met as evidenced by: Based on the survey on January 22, 2025, a review of the laboratory's policy and procedure, American Proficiency Institute (API) proficiency testing (PT) records, and an interview with the technical consultant (TC), it was determined that the laboratory failed to attain at least 80 percent of the acceptable score in Routine Chemistry for Albumin analyte in the second event of 2023 (Q2-2023), Ferritin analyte in the first event of 2023 (Q1-2023), and Carbon Dioxide (CO2) analyte in the first event of 2024 (Q1-2024). The findings include: 1. Based on the surveyor's review of PT records for Q2-2023 and Q1-2024, API reported an unsatisfactory score report as follows: a. Albumin PT Q2-2023 Overall score: 60% Specimen Reported Expected CHM-06 2.9 2.3 - 3.0 CHM-07 *4.6 3.6 - 4.5 CHM-08 2.2 1.8 - 2.3 CHM-09 *5.5 4.3 - 5.4 CHM-10 4.1 3.3 - 4.1 b. Ferritin PT Q1-2023 Overall score: 50% Specimen Reported Expected IA-01 189 152 - 208 IA-02 *188 11 - 19 c. CO2 PT Q1-2024 Overall score: 40% Specimen Reported Expected CHM-06 11 10 - 21 CHM-07 *15 23 - 34 CHM-08 *16 19 - 30 CHM-09 5 4 - 15 CHM-10 *22 27 - 40 2. The TC affirmed by interview on January 22, 2025, at approximately 11:00 a.m. that the laboratory obtained the PT scores mentioned in statement #1. 3. According to the laboratory's testing declaration submitted on the day of the survey, the laboratory performed approximately 118,862 Routine Chemistry test samples, including the Albumin, Ferritin, and CO2 analytes, during the time the laboratory received unsatisfactory proficiency testing results. Thus, the accuracy and reliability of patient test reports cannot be determined.</p>
D2098	ENDOCRINOLOGY

CFR(s): 493.843(a)

(a) Failure to attain a score of at least 80 percent of acceptable responses for each analyte in each testing event is unsatisfactory analyte performance for the testing event.

This STANDARD is not met as evidenced by:

Based on the survey on January 22, 2025, at approximately 11:00 a.m., review of the laboratory's policy and procedure, evaluation assessment of the American Proficiency Institute (API) proficiency testing (PT) records, and an interview with the technical consultant (TC), it was determined that the laboratory failed to attain at least 80 percent of the acceptable score in Endocrinology for multiple analytes in the in different testing events for the years 2022, 2023 and 2024. The findings include: 1. Based on the surveyor's assessment of PT records for the years 2022, 2023, and 2024, API reported an unsatisfactory score report as follows: a. In the second event for 2022 (Q2-2022), Free Thyroxine (FT4) scored 40%. b. In the third event of 2022 (Q3-2022), Free Triiodothyronine (FT3) scored 40%. c. In the first event of 2023 (Q1-2023), Testosterone and Vitamin B12 scored 50%. d. In the third event of 2023 (Q3-2023), Carcinoembryonic antigen (CEA) scored 0%. e. In the first event of 2024 (Q1-2024), FT3 scored 60%. f. In the third event of 2024 (Q3-2024), CEA scored 50%. 2. The TC affirmed by interview on January 22, 2025, at approximately 11:00 a.m. that the laboratory obtained the PT scores mentioned in statement #1 covering the years 2022, 2023, and 2024. 3. According to the laboratory testing declaration submitted at the time of the survey, the laboratory performed approximately 2,217 tests in the Endocrinology subspecialty during the time the laboratory received an unsatisfactory proficiency testing results in various testing events for FT4, FT3, Testosterone, Vitamin B12, and CEA analytes. Therefore, the reliability and quality of Endocrinology patient results reported cannot be assured.

D6014

LABORATORY DIRECTOR RESPONSIBILITIES

CFR(s): 493.1407(e)(3)(iii)

(e)(3)(iii) Laboratory personnel are performing the test methods as required for accurate and reliable results;

This STANDARD is not met as evidenced by:

Based on the cited deficiencies, the Laboratory Director is herein cited for failing in the responsibility for not ensuring that the testing personnel performing patient testing, including proficiency testing, maintain accuracy and reliability as required. See D2087 and D2098.